Immunogenicity and safety of pneumococcal conjugate polysaccharide and free polysaccharide vaccines alone or combined in HIV-infected adults in Brazil

Autor(es)

Ho, Yeh-Li ^[1] ; Brandao, Angela Pires ; de Cunto Brandileone, Maria Cristina ^[2] ; Lopes, Marta Heloisa ^[3]

Afiliação do(s) autor(es)

^[1] Univ Sao Paulo, Fac Med, Hosp Clin, Div Molestias Infecciosas & Parasitarias, BR-05403000 Sao Paulo - Brazil

^[2] Nucleo Meningites Pneumonias & Infeccoes Pneumoco, Ctr Bacteriol, Inst Adolfo Lutz, Recife, PE - Brazil

^[3] Univ Sao Paulo, Fac Med, Dept Molestias Infecciosas & Parasitarias, BR-05403000 Sao Paulo - Brazil

• Tipo de documento: Artigo Científico
• Fonte: Vaccine; v. 31, n. 37, p. 4047-4053, AUG 20 2013.
• Citações Web of Science: 21

Resumo

Background: Streptococcus pneumoniae is a leading cause of hospitalization in HIV-infected adults therefore pneumococcal vaccine is recommended. The ideal antipneumococcal vaccine and effective vaccination regimen remain controversial and needs further evaluation. Methods: To assess the efficacy of pneumococcal vaccines alone and combined, a randomized, blinded clinical trial was conducted in Brazil with 331 HIV-patients aged 18-60, with CD4-T cell count >= 200 cells/mm(3). Two interventions 60 days apart were done in three schedules: 23-valent pneumococcal polysaccharide vaccine (PPV23)/placebo; 7-valent pneumococcal conjugate vaccine (PCV7)/placebo; and PCV7 plus PPV23. Safety and reactogenicity were evaluated, and immunogenicity was assessed by an IgG enzyme-linked immunosorbent assay to S. pneumoniae serotypes 6B, By and 14, performed at baseline, 60 and 180 days after first intervention. Comparison of immunogenicity was based on geometric mean concentration (GMC), percentages of individuals with serotype-specific IgG >= 0.35 mu g/mL and >= 1.0 mu g/mL and proportion of individuals with >= 4-fold increase in specific antibody concentrations for each serotype. Results: Demographic and HIV conditions were similar, and both vaccines were well tolerated across vaccine groups. Significant increase in IgG-antibodies was observed to all serotypes evaluated. A greater proportion of PCV7 recipients reached and sustained IgG antibody concentrations at least four times as high as those at baseline, for serotypes 68 and 9V. A PPV23 dose after PCV7 did not enhance immunogenicity. Conclusions: In this first trial conducted with HIV-infected immunologically stable adults in South America, both PPV23 and PCV7 were safe and immunogenic. Evidence suggesting PCV7 was more immunogenic than PPV23, as it elicited higher and persistent >= 4-fold increase of antibodies for 6B and 9V serotypes in a greater proportion of HIV-patients is noteworthy. Despite current recommendation of schedules combining PCV7 and PPV23, there is little evidence to support this practice and we did not observe benefits in this combination. (C) 2013 Elsevier Ltd. All rights reserved. (AU)

• Processo FAPESP: 05/01414-7 - Comparação de resposta a vacinação com três esquemas diferentes da vacina anti-pneumococcica em indivíduos infectados pelo Vírus da Imunodeficiência Humana
• Beneficiário: Marta Heloísa Lopes
• Modalidade de apoio: Auxílio à Pesquisa - Regular